Patients on high-deductible health plans who pay for Ozempic based on its sticker price are set to see their monthly costs drop by roughly a third. Novo Nordisk announced it will cut the U.S. wholesale acquisition cost of Ozempic by approximately 35%, bringing the list price to $675 a month starting January 1, 2027. The reduction also applies to Wegovy and Rybelsus, the company’s other semaglutide medicines.
Who stands to pay less when Ozempic hits $675
The price cut is aimed squarely at people whose out-of-pocket spending is calculated directly from list price rather than from a net price negotiated behind the scenes by insurers and pharmacy benefit managers. That group includes patients enrolled in high-deductible plans who have not yet met their annual deductible, as well as those subject to coinsurance that is pegged to the published wholesale acquisition cost. For these patients, a new WAC of $675 per month translates into a direct reduction in what they owe at the pharmacy counter.
The distinction matters because most commercially insured patients never pay full list price. Rebates, discounts, and copay assistance programs already lower the effective cost for many, especially once they have met their deductibles or are in plans with flat copays. The announced change does not alter those rebate arrangements. It instead narrows the gap between the manufacturer-set sticker price and the real acquisition cost that pharmacies report to federal benchmarking systems. The federal government maintains the National Average Drug Acquisition Cost dataset, which tracks what pharmacies actually pay for drugs and serves as a reference point separate from list price.
Patients in Medicare Part D and Medicaid programs may see more complicated effects. Many of those plans base cost sharing on negotiated prices rather than WAC, and some low-income beneficiaries already have capped copays. For them, a lower list price might not immediately change what they pay at the counter, though it could influence plan bids and premiums over time. Uninsured patients who do not qualify for manufacturer assistance could benefit more directly, but only if pharmacies pass through a meaningful share of any reduction in their own acquisition costs.
Novo Nordisk’s $675 price tag and the pricing gap it narrows
Wholesale acquisition cost, or WAC, is the price a manufacturer sets before any rebates or discounts. It functions as the starting line for drug pricing in the U.S. supply chain. Pharmacies, insurers, and benefit managers all negotiate from that number. When a company lowers WAC, the immediate effect is felt most by patients and plan designs that use list price as their cost-sharing reference point.
The approximately 35% reduction for Ozempic, effective January 1, 2027, is part of a broader move covering all three of Novo Nordisk’s semaglutide products sold in the United States. The company framed the decision as building on continued efforts to expand access, signaling that list-price criticism and access concerns around weight-loss and diabetes drugs have become a strategic issue. Whether the lower WAC produces a detectable narrowing between published list prices and pharmacy acquisition costs tracked in the NADAC dataset within the first two quarters of 2027 will depend on how quickly the new price flows through distribution contracts.
The National Average Drug Acquisition Cost benchmark, maintained by federal agencies and accessible through the NADAC dataset, provides one of the clearest windows into how list prices compare to what pharmacies actually pay. Historically, high rebates have meant that net prices can diverge sharply from WAC. If existing rebate structures remain intact, Novo Nordisk’s net realized revenue per prescription could stay largely unchanged even as the headline price falls. In that scenario, the main winners would be patients whose cost sharing is explicitly tied to the sticker price, not the broader system.
Still, a lower WAC can influence negotiations over time. Pharmacy benefit managers often structure rebate guarantees and preferred formulary placement around percentage discounts off list. A cut to list price may prompt some renegotiation of those terms, particularly if payers see an opportunity to capture savings by shifting more patients to semaglutide therapies at a lower starting point. How aggressively plans pursue that strategy will depend on their own cost projections, utilization controls, and competing products.
Open questions after the Ozempic list-price announcement
Several gaps in the available record limit how far anyone can project the real-world impact. Novo Nordisk has not publicly detailed how the WAC reduction will interact with existing rebate contracts, or whether commercial payers will be offered revised terms as the 2027 effective date approaches. Without that information, it is difficult to estimate how much of the nominal 35% cut will flow through to premiums or employer spending.
Another unresolved issue is how quickly pharmacies and wholesalers will turn over inventory purchased at higher prices. If distributors hold significant stock bought before January 2027, patients could see a lag between the official WAC change and any adjustment in what they are charged, especially in cash-pay scenarios. Monitoring updates in the NADAC files during early 2027 will be one way to gauge how rapidly acquisition costs adjust in practice.
There are also broader policy questions. A high-profile list-price cut for semaglutide may add momentum to debates over whether manufacturers should be encouraged, or even required, to align WAC more closely with net prices. At the same time, if net revenues remain stable because rebates shrink as list prices fall, critics may argue that headline cuts do little to address underlying affordability concerns for patients whose cost sharing is already shielded from WAC.
For now, the clearest takeaway is targeted rather than sweeping. Patients who currently see their Ozempic, Wegovy, or Rybelsus bills calculated directly from list price are likely to experience a measurable drop in out-of-pocket costs when the $675 WAC takes effect. Everyone else-from insured patients on flat copays to employers and public programs-will have to wait for 2027 contract renewals, rebate adjustments, and updated acquisition-cost benchmarks to see whether the list-price move translates into broader financial relief.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
